Evidence map›Paper›PMID 31637414›Full record

ArticleNeuro-oncology2020

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.

C Mircea S Tesileanu, Linda Dirven, Maarten M J Wijnenga, Johan A F Koekkoek, Arnaud J P E Vincent, Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Sjoerd G van Duinen, Marion Smits and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

C Mircea S TesileanuDepartment of Neurology, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Linda DirvenDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Maarten M J WijnengaDepartment of Neurology, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Johan A F KoekkoekDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Arnaud J P E VincentDepartment of Neurosurgery, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Hendrikus J DubbinkDepartment of Pathology, the Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Peggy N AtmodimedjoDepartment of Pathology, the Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Johan M KrosDepartment of Pathology, the Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Sjoerd G van DuinenDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Marion SmitsDepartment of Radiology and Nuclear Medicine, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Martin J B TaphoornDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Pim J FrenchDepartment of Neurology, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Martin J van den BentDepartment of Neurology, the Brain Tumor Center, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) World Health Organization (WHO) grade II or III that present with (i) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or (ii) gain of chromosome 7 combined with loss of chromosome 10, and/or (iii) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). This paper describes the overall survival (OS) of IDH1/2wt astrocytoma WHO IV patients, and more in detail patients with tumors with pTERTmt only.

methodsIn this retrospective multicenter study, we compared the OS of 71 IDH1/2wt astrocytomas WHO IV patients, with radiological characteristics of LGGs, with the OS of 197 IDH1/2wt glioblastoma patients. Moreover, we compared the OS of 22 pTERTmt only astrocytoma patients with the OS of the IDH1/2wt glioblastoma patients.

resultsMedian OS was similar for IDH1/2wt astrocytoma WHO IV patients (23.8 mo) and IDH1/2wt glioblastoma patients (19.2 mo) (Cox proportional hazards model: hazard ratio [HR] 1.27, 95% CI: 0.85-1.88, P = 0.242). OS was also similar in patients with IDH1/2wt astrocytomas WHO IV, pTERTmt only, and IDH1/2wt glioblastomas (HR 1.15, 95% CI: 0.64-2.10, P = 0.641).

conclusionsThe presented data confirm the cIMPACT-NOW recommendation and we propose that IDH1/2wt astrocytomas WHO IV in the absence of other qualifying mutations should be classified as IDH1/2wt glioblastomas.

Indexed as

AstrocytomaBrain NeoplasmsGlioblastomaHumansIsocitrate DehydrogenaseMutationPrognosisRetrospective StudiesWorld Health OrganizationIDH1 protein, humanIsocitrate DehydrogenaseastrocytomacIMPACT-NOWglioblastomaIDHTERT

Identifiers

PMID31637414
PMCPMC7158657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.